Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 35 | ECE2014 | Next issue

16th European Congress of Endocrinology

Oral Communications

Bone, calcium & vitamin D

ea0035oc6.1 | Bone, calcium & vitamin D | ECE2014

Ucma as a direct common target of Runx2 and Osterix promotes osteoblast differentiation

Lee Yeon-Ju , Baek Ji-Eun , Kim Yeo Hyang , Choi Je-Yong , Kim Jung-Eun

Runx2 and Osterix(Osx) have been known as the master transcription factors for bone formation. However, genes that act downstream of both Runx2 and Osx have not been fully studied. To investigate downstream target genes of Runx2 and Osx, DNA microarray was conducted in calvaria of WT, Runx2ΔC/+, Osx+/−, and Runx2ΔC/+; Osx+/− double heterozygous mice designated WT, Runx2het, Osxhet, and Doub...

ea0035oc6.2 | Bone, calcium & vitamin D | ECE2014

High spontaneous osteoclastogenesis in pediatric osteogenesis imperfecta patients receiving or not intravenous neridronate

Faienza Maria Felicia , Tummolo Albina , Piacente Laura , Fiaschetto Rita , Ciccarelli Maria , Ventura Annamaria , Papadia Francesco , Colucci Silvia , Grano Maria , Cavallo Luciano , Brunetti Giacomina

Background: Osteogenesis imperfecta (OI) is a heritable disease of the connective tissues caused primarily by heterogeneous mutations in the genes encoding for type I collagen. Phenotypically, it is characterized by abnormal bone mineralization, tissue fragility, and skeletal deformities.Objective: The aim of this study was to investigate the osteoclastogenic potential of unfractionated peripheral blood mononuclear cells (PBMCs) from OI patients (mean ag...

ea0035oc6.3 | Bone, calcium & vitamin D | ECE2014

Hypoparathyroidism: The burden of illness and impact on patients' personal lives

Clarke Bart , Sanders James , Lagast Hjalmar

Hypoparathyroidism, a rare endocrine disorder of insufficient parathyroid hormone, leads to hypocalcemia and often hyperphosphatemia. The PARADOX study assessed the clinical and personal disease impact from the affected patients’ perspective.Patients ≥18 years and diagnosed ≥6 months ago completed a non-validated, self-reported, web-based survey.Three hundred and seventy-four US adults (mean age, 49 years; women, 8...

ea0035oc6.4 | Bone, calcium & vitamin D | ECE2014

The REPEAT Study: An open-label clinical trial evaluating the safety and efficacy of recombinant human parathyroid hormone, rhPTH(1–84), for the treatment of hypoparathyroidism in hungary

Lakatos Peter , Bajnok Laszlo , Lagast Hjalmar , Valkusz Zsuzsanna

In hypoparathyroidism, inadequate levels of parathyroid hormone (PTH) result in hypocalcemia and often hyperphosphatemia. Large doses of calcium (Ca) and active vitamin D are typically used to manage symptoms, although these are often associated with complications and do not address the underlying PTH deficiency. In the phase III REPLACE trial, 24 weeks of treatment with rhPTH(1–84) was associated with maintained serum Ca without urine Ca excretion increases despite clini...

ea0035oc6.5 | Bone, calcium & vitamin D | ECE2014

The effect of recombinant human parathyroid hormone, rhPTH(1–84), on vitamin D metabolism and phosphate homeostasis: Results from phase III 24-Week REPLACE and phase I clinical studies

Brandi Maria Luisa , Beckers Albert , Vokes Tamara , Mannstadt Michael , Bilezikian John , Clarke Bart , Lagast Hjalmar , Shoback Dolores

PTH promotes conversion of 25-hydroxyvitamin D (25[OH]D) to 1,25-dihydroxyvitamin D (1,25[OH]2D), thus stimulating intestinal calcium and phosphate absorption. Because of low PTH levels in hypoparathyroidism, patients are prescribed calcitriol. Patients are predisposed to hyperphosphatemia owing to loss of PTH-stimulated phosphate excretion by the kidneys. Effects of rhPTH(1–84) on vitamin D metabolism and serum phosphate were studied.In ...